Evercore ISI analyst Gavin Clark-Gartner lowered the firm’s price target on Dyne Therapeutics (DYN) to $36 from $38 and keeps an Outperform rating on the shares. Efficacy and safety metrics are meeting expectations with positive trends on functionality, which is “encouraging” following the company’s recent fundraising, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics price target raised to $39 from $36 at Stifel
- Dyne Therapeutics Announces Upsized Public Offering
- Amazon initiated, GE Vernova upgraded: Wall Street’s top analyst calls
- Oppenheimer upgrades Dyne Therapeutics to Outperform, raises target to $40
- Dyne Therapeutics upgraded to Outperform from Perform at Oppenheimer